Appointment of Director

18 August 2011

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                            Appointment of Director                            

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, is pleased to announce the appointment of Katherine Cornish-Bowden as
a non-executive director with immediate effect.

Kate (44) is a Chartered Financial Analyst and holds a Masters in Business
Administration. She was managing director and head of Morgan Stanley Investment
Management's Global Core Equity Team between 2002 and 2004. Prior to this she
was an executive director and senior portfolio manager within the same team at
Morgan Stanley. More recently Kate has acted as a consultant providing
financial research to private equity and financial training firms and was
appointed a director of Investec Structured Products Calculus VCT plc in
February 2011.

Kate was formerly a director of KCB Research Limited which was voluntarily
removed from the Register of Companies on 12 August 2009.

There are no other requirements to be disclosed under Schedule Two, paragraph
(g) of the AIM Rules for Companies.

David Evans commented "I very much welcome Kate onto Scancell's Board, we are
fortunate to have been able to attract someone of Kate's calibre and she will
make an invaluable contribution to the Scancell Board going forward."

For further information contact:

Scancell Holdings Plc                                + 44 (0)207 245 1100 
Professor Lindy Durrant/Dr Richard Goodfellow                             
                                                                          
Hansard Communications- Financial PR                 + 44 (0)207 245 1100 
Adam Reynolds/Guy McDougall                                               
                                                                          
Zeus Capital - Nominated Adviser                     + 44 (0)161 831 1512 
Ross Andrews/Tom Rowley                                                   
                                                                          
XCAP Securities Plc - Broker                         [phone] 
Jon Belliss/Parimal Kumar                                                 

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1, which entered clinical trials
in 2010, is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.

The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.